foxo4 dri senolytic peptide human trial 2024 FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice The disordered p53 transactivation domain

The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Full article: Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics Targeting Cellular Senescence in Aging and Age Related Diseases: Challenges, Considerations, and the Emerging Role of Senolytic and Senomorphic Therapies Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv

SKU: 36275994442 · From cantondelareina.com.ar